Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


PDUFA VI launches: Not Pluto flyby, but has potential

This article was originally published in Scrip

Executive Summary

While the launch of the sixth round of the Prescription Drug User Fee Act (PDUFA), which officially got underway on 15 July, was far less dramatic than the Pluto flyby, the process ahead for the FDA and the biopharmaceutical industry, nonetheless, has the potential to boost scientific innovation and speed new therapies and cures to the market – helping to make life better for those down on Earth, declared Dr Stephen Ostroff, acting commissioner of the FDA.

Related Content





Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts